Sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF, marketed as Leukine®) was evaluated in a Phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The rationale stemmed from the hypothesis that immunomodulation, particularly targeting the innate immune system, might provide neuroprotective benefits in ALS[@gmcsf2007].
GM-CSF is a cytokine that stimulates the production and differentiation of white blood cells, particularly granulocytes and macrophages. Beyond its well-known hematopoietic effects, GM-CSF has been shown to have immunomodulatory properties in the central nervous system, where it can influence microglial function and potentially promote neuroprotection[@engelen2002].
Trial Details
NCT Number: NCT00035862
Phase: Phase 2
Status: Completed (Results published)
Sponsor: National Institutes of Health (NIH)
Drug: Sargramostim (Leukine®)
Dosage: 5-7 μg/kg subcutaneously daily
Patient Population: Adults with definite or probable ALS (El Escorial criteria)
Sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF, marketed as Leukine®) was evaluated in a Phase 2 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS). The rationale stemmed from the hypothesis that immunomodulation, particularly targeting the innate immune system, might provide neuroprotective benefits in ALS[@gmcsf2007].
GM-CSF is a cytokine that stimulates the production and differentiation of white blood cells, particularly granulocytes and macrophages. Beyond its well-known hematopoietic effects, GM-CSF has been shown to have immunomodulatory properties in the central nervous system, where it can influence microglial function and potentially promote neuroprotection[@engelen2002].
Trial Details
NCT Number: NCT00035862
Phase: Phase 2
Status: Completed (Results published)
Sponsor: National Institutes of Health (NIH)
Drug: Sargramostim (Leukine®)
Dosage: 5-7 μg/kg subcutaneously daily
Patient Population: Adults with definite or probable ALS (El Escorial criteria)
ALS is characterized by progressive loss of upper and lower motor neurons. Post-mortem studies consistently reveal extensive neuroinflammation in the spinal cord and motor cortex of ALS patients, with activated microglia surrounding degenerating motor neurons. This neuroinflammation is thought to contribute to disease progression through several mechanisms:
Pro-inflammatory Cytokines: Elevated TNF-α, IL-1β, and IL-6 in ALS spinal cord
Immune Cell Infiltration: Peripheral immune cells infiltrating the CNS
Oxidative Stress: Inflammation-driven oxidative damage to motor neurons
GM-CSF as Immunomodulator
The rationale for using GM-CSF in ALS was based on its dual immunomodulatory properties:
Peripheral Immune Effects: GM-CSF stimulates monocytes and dendritic cells, potentially shifting the immune response toward a more protective phenotype
CNS Microglial Modulation: GM-CSF can cross the blood-brain barrier and directly affect microglial function, promoting a neuroprotective (M2-like) phenotype
Trophic Factor Production: GM-CSF may induce production of neurotrophic factors that support motor neuron survival[@zhao2007]
Mechanism of Action
GM-CSF exerts immunomodulatory effects through multiple pathways:
Immune Cell Modulation
Microglial Activation: Modulates microglial phenotype and function from pro-inflammatory (M1) to neuroprotective (M2) state
Monocyte Function: Enhances monocyte/macrophage activity and phagocytic capacity
Dendritic Cells: Affects antigen-presenting cell function and immune surveillance
Neuroprotective Effects
Neuroinflammation Reduction: May shift microglia toward protective phenotype, reducing production of neurotoxic inflammatory mediators
Trophic Factor Production: May increase neurotrophic factor release from immune cells (e.g., BDNF, GDNF)
Immune Surveillance: Enhances immune cell surveillance in CNS, potentially clearing debris and toxic proteins
[Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: HNRNPA2B1
Related Analyses:
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Sargramostim (GM-CSF) ALS Trial discovered through SciDEX knowledge graph analysis: